Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology Jg. 16; H. 4; S. 271 - 281
Hauptverfasser:	Kalincik, Tomas, Brown, J William L, Robertson, Neil, Willis, Mark, Scolding, Neil, Rice, Claire M, Wilkins, Alastair, Pearson, Owen, Ziemssen, Tjalf, Hutchinson, Michael, McGuigan, Christopher, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Alroughani, Raed, Pucci, Eugenio, Sola, Patrizia, Hupperts, Raymond, Lechner-Scott, Jeannette, Terzi, Murat, Van Pesch, Vincent, Rozsa, Csilla, Grand'Maison, François, Boz, Cavit, Granella, Franco, Slee, Mark, Spitaleri, Daniele, Olascoaga, Javier, Bergamaschi, Roberto, Verheul, Freek, Vucic, Steve, McCombe, Pamela, Hodgkinson, Suzanne, Sanchez-Menoyo, Jose Luis, Ampapa, Radek, Simo, Magdolna, Csepany, Tunde, Ramo, Cristina, Cristiano, Edgardo, Barnett, Michael, Butzkueven, Helmut, Coles, Alasdair
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.04.2017 Elsevier Limited
Schlagworte:	Adult Alemtuzumab Antibodies, Monoclonal, Humanized - therapeutic use Clinical medicine Clinical trials Cohort Studies Data entry Databases, Bibliographic - statistics & numerical data Disability Evaluation Female Fingolimod Hydrochloride - therapeutic use Humans Immunologic Factors - therapeutic use Immunotherapy Interferon Interferon-beta - therapeutic use Male Medical research Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab - therapeutic use Neurology Pharmaceutical industry Quality Studies Treatment Outcome Young Adult
ISSN:	1474-4422, 1474-4465, 1474-4465
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!